• Profile

Methotrexate treatment in rheumatoid arthritis and elevated liver enzymes: A long-term follow-up of predictors, surveillance, and outcome in clinical practice

International Journal of Rheumatic Diseases Apr 29, 2019

Sundbaum JK, et al. - From January 2005 to April 2013 at a rheumatology clinic, (Uppsala University Hospital, Sweden), researchers analyzed the predictors of alanine aminotransferase (ALT) elevation in methotrexate (MTX) treated rheumatoid arthritis (RA) patients, and also illustrated the monitoring of liver enzymes, including handling and outcome of elevated ALT. They performed 6288 ALT tests during a mean follow-up of 4.3 years whereas 7% of tests with ALT were more than upper limit of normal (ULN). In 70% of patients who continued treatment recurrent elevations appeared. Similar proportion was observed in those with and without interventions, for example, MTX dose reduction (67% vs 73%). The strongest predictor for early and recurrent ALT elevations during therapy was pre-treatment elevation of ALT.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen